Ampsource Biopharma Shanghai Inc.

Pharmab, Inc.

Furen Pharmaceutical Group Co., Ltd

Kaifeng Pharmaceutical (Group) Co., Ltd.

Yuanli Li

Qiang Li

Yuncheng Zheng

Xinlu Ma

Yongjuan Gao

Lu Yang

Naichao Sun

Si Ruo Chen

Zirui Li

Zhao Dong

Zhu Wang

Tongtong Xue

Liang Xiao

Dengnian Liu

Qilei Wang

Shixiang Jia

Jie Gao

Shuya Wang

Wenwen Wang

Zijia Ren

Bin Liu

Kangyong Zhu

Jianyu Sun

Jiangjiang Hu

Wenchen Zhu

Chenggong Zhu

Hongsheng Su

Songlin Zhu

Luyan Zhu

Lirui Wang

Xiaoshan Wang

Ming Jiang

Zhi Li

Yuan Yan

Yuhua Zhang

Li Zhou

Yao Xiong

Rilong Sun

Xuemei Liu

Jiasheng Diao

Chi Zhou

Provided by the present invention are an antibody against human TIM-3 or an antigen-binding fragment thereof, and further provided are a nucleic acid molecule encoding the antibody, an expression vector for expressing the antibody and a host cell, and a method for producing the antibody. Further provided by the present invention are a pharmaceutical composition comprising the antibody or an antigen-binding fragment of the antibody, and an application of the pharmaceutical composition in the preparation of a medicine, the medicine is used for preventing and/or treating various diseases (including tumors, infectious diseases and autoimmune diseases).

Antibody against TIM-3 and application thereof

A linker peptide for constructing a fusion protein. The linker peptide comprises a flexible peptide and a rigid peptide. The flexible peptide consists of one or more flexible units. The rigid peptide consists of one or more rigid units. The flexible unit comprises two or more amino acid residues selected from Gly, Ser, Ala, and Thr. The rigid unit comprises a human chorionic gonadotropin &#x3b2;-subunit carboxy-terminal peptide (CTP) bearing a plurality of glycosylation sites. The linker peptide can more effectively eliminate mutual steric hindrance of two fusion molecules, decreasing a reduction/loss of polymerization or activity resulting from improper folding of an active protein or a conformational change. On the other hand, the negatively charged, highly sialylated CTP can resist renal clearance, further prolonging a half-life of a fused molecule and enhancing bioavailability of a fused protein. Furthermore, a protective effect of a glycosylated side chain CTP can lower the protease sensitivity of the linker peptide, making a linker region of the fusion protein less degradable.

Linker peptide for constructing fusion protein

A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin &#x3b2;-subunit carboxyl terminal peptide, and a half-life extending portion (preferentially selected from a human IgG Fc variant). The fusion protein has a similar level of biological activity as a recombinant (FVIII) and an extended in vivo half-life, thereby improving pharmacokinetics and drug efficacy.

Highly glycosylated human blood-clotting factor VIII fusion protein, and manufacturing method and application of same

This disclosure provides an antibody specifically binding to PD-1 with high affinity. Also provided are a nucleic acid molecule for coding the antibody, an expression vector and a host cell for expressing the antibody, and a production method for the antibody. In addition, also provided are an immunoconjugate and a pharmaceutical composition comprising the antibody and use of the antibody in preparation of drugs for treating cancers, infectious diseases, and inflammatory diseases.

Anti-PD-1 antibody and use thereof

Growing community of inventors

Shanghai, China

Yuanli Li